Baxter to proceed with longer-acting Advate
This article was originally published in Scrip
Executive Summary
Baxter is progressing with the development of a longer-acting Advate product for the treatment of hemophilia A. The company has filed an IND for BAX 855 with the US FDA following positive Phase I results. Using PEGylation technology through a collaboration with Nektar Therapeutics, the half-life of BAX 855 in the body measured in the Phase I trial was around 1.5-fold higher compared to Advate.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.